HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Efforts to address opioid epidemic must limit overuse without restricting access for cancer pain control
-
- Association honors AMA president-elect
- False-positive mammograms lead to greater prescription use for anxiety, depression
- Research Center appoints director
- Three elected to ASH executive committee
- Underutilized test may improve treatment decisions, outcomes in colon cancer
- Neuro-oncologist receives NIH award
- Tobacco, alcohol and cancer: Not always black and white John Sweetenham, MD, FRCP, FACP
- Copanlisib approved for follicular lymphoma
-
- Pembrolizumab approved for certain gastric cancers
- Letermovir approved to prevent cytomegalovirus following HSCT
- Complete blood cell count test cleared with broad access
- Acalabrutinib receives accelerated approval for mantle cell lymphoma
- Elacestrant receives fast track designation for breast cancer subtype
- LN-144 receives fast track designation for advanced melanoma
- ATA230 receives orphan drug designation for cytomegalovirus
- PCM-075 receives orphan drug designation for AML
-
- Adapted blood test predicts risk for anemia following malaria treatment
- ASCO: Even light alcohol use increases risk for cancer
- BRAF V600E worsens outcomes in pediatric low-grade gliomas
- Breast cancer subtype does not predict response to radiotherapy
- Cancer drug revenue substantially higher than R&D spending
- CDC: Most cancers associated with obesity, overweight on the rise
- Clonal evolution predicts myelodysplastic syndrome progression
- Colorectal cancer rates rising dramatically in young adults
-
- Comprehensive cancer survivorship services lacking in primary care
- Consolidation with arsenic trioxide effective for pediatric acute promyelocytic leukemia
- Daratumumab regimen shows promise in relapsed, refractory multiple myeloma
- Early prostate cancer survival similar after radical prostatectomy, observation
- Failed study shows need for esophageal cancer biomarkers
- Formula predicts survival among adults with graft-versus-host disease
- Gene profile may predict risk for stroke in sickle cell anemia
- HER-2 mutation found in advanced lung cancer
-
- Highly educated patients with acute myeloid leukemia show better survival in a universal health system
- Liquid biopsy offers option for EGFR testing without lung tumor tissue
- Cerebrospinal fluid lymphoblasts at diagnosis impact prognosis in B-cell acute lymphoblastic leukemia
- Men with prostate cancer willing to pay more for advanced biopsies
- Midostaurin extends survival in acute myeloid leukemia with FLT3 mutation
- Most patients with cancer curious about marijuana use
- Pembrolizumab superior to ipilimumab in advanced melanoma
- Perioperative interruption of direct oral anticoagulants safe, effective
-
- Proton beam therapy shows promise for non-small cell lung cancer
- Researchers identify biomarkers for CAR T-cell therapy neurotoxicity
- Surgery-based regimen improves survival in malignant pleural mesothelioma
- Survivors of childhood cancer experience differences in psychosexual development
- Axitinib-pembrolizumab combination shows promise in advanced alveolar soft part sarcoma
- Free texting service keeps patients’ families updated during cancer surgeries
- Gottlieb sees ‘watershed opportunity’ to shape future of FDA’s regulatory process
- Ideal treatment for older adults with metastatic renal cell carcinoma remains unclear
-
- Larotrectinib enables children with sarcoma to proceed to surgery
- Lay navigators improve quality of cancer care, reduce costs
- Nivolumab active in metastatic non-clear cell renal cell carcinoma
- Pembrolizumab doubles median OS for metastatic NSCLC
- Pretreatment neutrophil-to-lymphocyte ratio predicts outcomes in metastatic renal cell carcinoma
- Proposed tumor classification criteria appears accurate for non-small cell lung cancer
- Sarcoma coding often inaccurate
- Surveillance, ablation important for management of small renal masses
-
- VEGF inhibitors may augment immunotherapy efficacy for first-line renal cell carcinoma
- Rh-Endostatin in perioperative period improves osteosarcoma outcomes
- Should all patients with cancer undergo an addiction risk assessment prior to receiving opioids?